title: Malignancy and the Risks of Biologic Therapies: Current Status.
abstract: Cancer is a common event in patients with rheumatic diseases. In some cases, the disease, its risk factors, or its treatment could play a role in favoring cancer. This article analyzes the current knowledge on the risk of malignancy associated with biologics in rheumatic diseases and discusses some methodological issues to be considered when evaluating the association between disease, treatments, and the risk of cancer. This article focuses on the risk of overall malignancy but also of skin cancer, lymphoma, and recurrent cancer associated with all biologics marketed for the treatment of rheumatic diseases.
authors.affiliation: INSERM U1184, Assistance Publique-Hôpitaux de Paris (AP-HP), Center of Research on Immunology of Viral and Autoimmune Diseases (IMVA), Université Paris-Sud, Le Kremlin Bicêtre, France; Department of Rheumatology, Hôpitaux Universitaires Paris-Sud, Hôpital Bicêtre, 78 rue du Général Leclerc, Le Kremlin Bicêtre 94275, France. Electronic address: raphaele.se@gmail.com.
authors.forename: Raphaèle
authors.initials: R
authors.lastname: Seror
authors.affiliation: INSERM U1184, Assistance Publique-Hôpitaux de Paris (AP-HP), Center of Research on Immunology of Viral and Autoimmune Diseases (IMVA), Université Paris-Sud, Le Kremlin Bicêtre, France; Department of Rheumatology, Hôpitaux Universitaires Paris-Sud, Hôpital Bicêtre, 78 rue du Général Leclerc, Le Kremlin Bicêtre 94275, France.
authors.forename: Xavier
authors.initials: X
authors.lastname: Mariette
mesh_terms: D018501:Antirheumatic Agents / Q000009:adverse effects*; D001688:Biological Products / Q000009:adverse effects*; D006801:Humans; D009369:Neoplasms / Q000139:chemically induced* / Q000276:immunology; D012216:Rheumatic Diseases / Q000188:drug therapy* / Q000276:immunology
chemical_list: D018501:Antirheumatic Agents; D001688:Biological Products
keywords: Abatacept; Anti-TNF/TNF inhibitors; Biologic therapies; Lymphoma; Rituximab; Skin cancer; Tocilizumab